Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:23:06.541Z.
Calculation as of: 2026-10-06T21:23:06.541Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 64600f38e310d2eb3cd81a0b95bf77f6abd31b9de5548b9cdd3f3c9d46967593
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
PROCEPT BioRobotics Corporation
Market Cap
$996.65M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$998.69M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$982.46M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
Price/FCF Ratio
N/A
TTM Avg
31.06
3Y Avg
31.06
5Y Avg
31.06
Market Cap
$978.09M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
Price/FCF Ratio
N/A
TTM Avg
56.73
3Y Avg
40.99
5Y Avg
56.97
Market Cap
$973.93M
Price/FCF Ratio
5.43
TTM Avg
7.51
3Y Avg
7.85
5Y Avg
14.47
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporation (PRCT) | $996.65M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | N/A | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | 6.28 | 5.25 | 24.15 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | N/A | 31.06 | 31.06 | 31.06 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | N/A | 56.73 | 40.99 | 56.97 |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 5.43 | 7.51 | 7.85 | 14.47 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | N/A | 558.39 | 558.39 | 558.39 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
